Results 131 to 140 of about 11,499 (250)

Evaluation of Electrodermal Activity in Diabetic Rats Treated with Vildagliptin and Metformin

, 2022
Miftah Mohammed Miftah Alshawesh
openalex   +2 more sources

Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes

, 2013
Plamen Kozlovski
openalex   +1 more source

Larger Efficacy on Combined Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) By Bis in Die (Bid) Administration

, 2023

openalex   +1 more source

ERRATUM: Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction. [PDF]

J Endocrinol
Apaijai N, Inthachai T, Lekawanvijit S, Chattipakorn SC, Chattipakorn N.   +4 more
europepmc   +1 more source

Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis [PDF]

, 2013

core   +1 more source

Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes

, 2009
Adrian Vella, Smushkin
openalex   +1 more source

Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan. [PDF]

Drugs Real World Outcomes
Takami A, Terashima G, Tajima T, Yamashita K, Igarashi A.   +4 more
europepmc   +1 more source

Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). [PDF]

PLoS One
Xiong W, Li Y, Huang J, He G, Sun J.
europepmc   +1 more source

Comparative Evaluation of the Effects of Oral Anti-hyperglycemic Agents and an Ayurvedic Hepatoprotective Agent in a Rat Model of Non-alcoholic Fatty Liver Disease (NAFLD). [PDF]

Cureus
Kalra SSS, Sadasivam B, Najmi A, Chaurasia JK.   +3 more
europepmc   +1 more source

Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting [PDF]

, 2015

core   +1 more source